araag2/HINT huggingface dataset:
Clinical trial NCT00002717 (phase 3, status: completed)
Conditions: ovarian cancer, primary peritoneal cavity cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: cisplatin, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed primary ovarian epithelial cancer or
        primary peritoneal cancer Suboptimal residual disease within 6 weeks of laparotomy with
        maximum resection Stage III residual retroperitoneal disease greater than 1 cm and no
        greater than 1 cm residual intraperitoneal disease OR Stage IV disease The following
        histologies are eligible: Serous adenocarcinoma Malignant Brenner's tumor Mucinous
        adenocarcinoma Endometrioid adenocarcinoma Undifferentiated carcinoma Clear cell
        adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Adenocarcinoma not
        otherwise specified Measurable disease not required Cytologic confirmation of malignant
        pleural effusion required if sole basis of entry No borderline (low malignant potential)
        carcinoma No unclassified ovarian cancer, i.e., thought to be of ovarian origin but
        unexplored or unable to verify tumor arising from ovarian stroma

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Hematopoietic: WBC at
        least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal AST, ALT, and GGT no
        greater than 3 times normal Alkaline phosphatase no greater than 3 times normal LDH no
        greater than 3 times normal No acute hepatitis Renal: Creatinine no greater than 2 mg/dL
        Cardiovascular: No history of congestive heart failure No history of unstable angina No
        myocardial infarction within 6 months Other: No severe infection, including septicemia No
        severe gastrointestinal bleeding No history of second malignancy within 5 years except
        nonmelanomatous skin cancer Not pregnant or nursing Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:
        See Disease Characteristics No more than 6 weeks since staging laparotomy and primary
        cytoreductive surgery
Clinical trial NCT00604279 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate (r092670), risperidone
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who meet diagnostic criteria for schizophrenia according to Diagnostic
             and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (disorganized type
             [295.10], catatonic type [295.20], paranoid type [295.30], residual type [295.60], or
             undifferentiated type [295.90]) for at least 1 year before screening and prior medical
             records, written documentation, or verbal information obtained from previous
             psychiatric providers obtained by the investigator must be consistent with the
             diagnosis of schizophrenia

          -  A total Positive and Negative Syndrome Scale (PANSS) score between 60 and 120,
             inclusive, at screening and baseline

          -  Body mass index (BMI) of equal to or greater than 17.0 kilogram per meter square
             (kg/m^2)

          -  Female participants must be postmenopausal for at least 2 years, surgically sterile,
             abstinent, or, if sexually active, be practicing an effective method of birth control
             before study entry and throughout the study

          -  Be capable of self-administering study medication (applies to oral supplementation) or
             have assistance with study medication administration consistently available throughout
             the first 4 weeks of the study Exclusion Criteria:

          -  A primary, active DSM-IV diagnosis on Axis I other than schizophrenia

          -  A decrease of at least 25 percent in the total PANSS score between screening and
             baseline

          -  Participants who have previously participated in this study

          -  A DSM-IV diagnosis of active substance dependence within 3 months before screening
             (nicotine and caffeine are not exclusionary)

          -  History of treatment resistance as defined by failure to respond to 2 adequate
             treatments with different antipsychotic medications (an adequate treatment is defined
             as a minimum of 6 weeks at maximum tolerated dosage)
Clinical trial NCT00705575 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren/hydrochlorothiazide (hctz) (300/25 mg), aliskiren (300 mg)
SMILES: COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients ≥18 years of age.

          -  Patients with a diagnosis of Stage II hypertension, defined as mean sitting Systolic
             Blood Pressure (msSBP) ≥ 160 mmHg and < 180 mmHg at Visit 2.

        Exclusion Criteria:

          -  Severe hypertension defined as msSBP ≥ 180 mmHg and/or mean sitting Diastolic Blood
             Pressure (msDBP) ≥ 110 mmHg.

          -  Secondary form of hypertension.

          -  Current diagnosis of heart failure (New York Heart Association [NYHA] Class II-IV).

          -  Current angina pectoris requiring pharmacological therapy (other than stable doses of
             oral or topical nitrates).

          -  Second or third degree heart block without a pacemaker.

          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia, atrial
             fibrillation or atrial flutter, during the 12 months prior to Visit 1.

          -  Clinically significant valvular heart disease.

          -  Previous history of hypertensive encephalopathy or stroke, Transcient Ischemic Attack
             (TIA), heart attack, coronary bypass surgery or any PCI.

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  In the month prior to Visit 1, patients on combination antihypertensive therapy that
             includes more than 2 classes of antihypertensive medications.

          -  Patients on combined antihypertensive medication that contain two classes of
             antihypertensive medications are considered to take two antihypertensive medications.

          -  Inability to discontinue prior antihypertensive or other CV medications as required by
             the protocol.

          -  Patients with Type 1 diabetes mellitus.

          -  Patients with Type 2 diabetes mellitus not well controlled .

          -  Elevated Serum potassium (over 5.3 mEq/L (mmol/L).

          -  Any surgical or medical condition or the use of any medication which might
             significantly alter the absorption, distribution, metabolism, or excretion of study
             drugs.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00057928 (phase 3, status: withdrawn)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: cisplatin, gemcitabine hydrochloride, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of primary carcinoma of the cervix, meeting 1 of the following staging
             criteria:

               -  Metastatic (stage IVB)

               -  Recurrent after prior complete response to primary treatment with surgery or
                  radiotherapy

               -  Persistent after surgery or radiotherapy

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age

          -  Not specified

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Creatinine less than upper limit of normal OR

          -  Creatinine clearance greater than 40 mL/min

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No grade 2 or greater sensory or motor neuropathy

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer currently in complete remission

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 6 months since prior single-agent chemotherapy as a radiosensitizer

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  At least 28 days since prior radiotherapy

          -  No prior radiotherapy to measurable target lesions

          -  No concurrent palliative radiotherapy

        Surgery

          -  See Disease Characteristics

          -  Recovered from prior surgery

        Other

          -  No prior systemic therapy

          -  No other concurrent antitumor therapy
Clinical trial NCT00187135 (phase 3, status: terminated)
Conditions: bone marrow disease, pain
ICD codes: Z52.3, T86.01, T86.02, T86.03, Z94.81, C79.52, T86.00, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: fentanyl, emla, l.m.x4, propofol
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CCCNC(C)C(=O)NC1=CC=CC=C1C, OC(=O)[C@@H]1CCCN1
Reason stopped: 
    the study was terminated due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing bone marrow aspiration (unilateral), with lumbar puncture and
             intrathecal chemotherapy.

          -  Age 2 to 17 years

          -  ASA I-III

          -  Patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in remission or
             on the day of anticipated remission procedures occurring at the end of remission
             induction.

          -  Patients must have three anticipated bone marrow aspirates and lumbar punctures with
             intrathecal chemotherapy remaining in their treatment

        Exclusion Criteria:

          -  Newly diagnosed patients

          -  Patients with low platelet count (less than 50000)

          -  Patients undergoing bone marrow biopsy in addition to bone marrow aspiration

          -  Age less than 2 years or over 17 years

          -  ASA IV-V

          -  Patients taking opioid medication for pre-existent pain for more than 2 weeks at the
             time of the procedure

          -  Neurological impairment that would increase susceptibility to opioids (Down's
             syndrome)

          -  Clinical contraindications for general anesthesia (large mediastinal mass) or specific
             use of propofol, Fentanyl, EMLA, L•M•X 4™ or Lidocaine for injection
Clinical trial NCT00255190 (phase 3, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: dexlansoprazole mr, dexlansoprazole mr
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have successfully completed either T-GD04-082 (NCT00251745) or
             T-GD04-083 (NCT00251758) or have a diagnosis of gastroesophageal reflux disease with
             or without erosive esophagitis.

        Exclusion Criteria:

          -  Any condition that may require inpatient surgery during the course of the study.

          -  Use of prescription or non-prescription proton pump inhibitors, histamine (H2)
             receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study.

          -  Use of antacids [except for study supplied Gelusil®].

          -  Subjects using drugs with significant anticholinergic effects such as tricyclics who
             cannot stay on a stable dose for 4 weeks prior to dosing and throughout the study.

          -  Evidence of uncontrolled systemic disease.

          -  Allergy to any proton pump inhibitor including Prilosec, Nexium, Prevacid, or others,
             any component of dexlansoprazole MR, or Gelusil/antacid.

          -  Need to take blood thinners.

          -  Need to take more than 12 doses of non-steroidal anti-inflammatory drugs per month.

          -  Had cancer (except basal cell cancer of the skin) within 3 years prior to screening.

          -  Has other esophageal disease including Barrett's esophagus or strictures requiring
             dilation.

          -  Has had radiation or cryotherapy to the esophagus.

          -  Has active gastric or duodenal ulcers within 4 weeks of starting study drug.

          -  Has a history of hypersecretory conditions such as Zollinger Ellison Syndrome.

          -  History of alcohol abuse.

          -  Has acquired immunodeficiency syndrome.

          -  Has had acute upper gastrointestinal bleeding within 4 weeks of endoscopy.

          -  Received a blood product transfusion within 3 months of taking the first dose of study
             drug.

          -  Has previously participated in another dexlansoprazole MR long-term treatment clinical
             trial.
Clinical trial NCT00383422 (phase 3, status: completed)
Conditions: osteoporosis, postmenopausal
ICD codes: N95.0, N95.2
Drugs: arzoxifene, raloxifene
SMILES: COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have osteoporosis

          -  Must be between 50 and 75 years old and be able to walk

          -  Have at least two of your back bones that can be x-rayed

          -  Have not had a period in at least two years

          -  Be willing to have blood tests

        Exclusion Criteria:

          -  Have a bone disease other than osteoporosis

          -  History of estrogen dependent cancer

          -  History of stroke or certain heart problems

          -  Possibly have an allergy to raloxifene or arzoxifene

          -  Have certain abnormal lab values

          -  History of seizure disorder

          -  Have unexplained vaginal bleeding or an abnormal pap smear
Clinical trial NCT00251927 (phase 3, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: esomeprazole
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects considered suitable for surgical treatment and long-term management of
             esomeprazole.

          -  History of chronic reflux esophagitis or symptomatic GERD

        Exclusion Criteria:

          -  History of esophageal, gastric, or duodenal surgery predicted to influence negatively
             on subsequent treatment within the study.

          -  Contraindication to the study drug.

          -  Pregnancy, lactating or of child-bearing potential.
Clinical trial NCT00055731 (phase 3, status: active, not recruiting)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: bicalutamide, goserelin acetate, docetaxel, estramustine phosphate sodium, acetylsalicylic acid
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Locally advanced disease or at high risk for relapse

          -  No clinically or radiologically suspected metastases

          -  Prior lymphadenectomy required

          -  Meets at least 1 of the following criteria for poor prognosis:

               -  Gleason score greater than 7

               -  T3 or T4 disease

               -  Prostate-specific antigen greater than 20 ng/mL

               -  N1 disease

        PATIENT CHARACTERISTICS:

        Age

          -  Under 80

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  More than 10 years

        Hematopoietic

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  AST and ALT no greater than 1.5 times upper limit of normal (ULN)

          -  Bilirubin no greater than ULN

        Renal

          -  Creatinine less than 1.6 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular

          -  No uncontrolled or severe cardiovascular disease

          -  No prior thrombosis

        Pulmonary

          -  No prior pulmonary embolus

        Other

          -  No active infection

          -  No intolerance to aspirin

          -  No other prior malignancy except basal cell skin cancer

          -  No physical or psychological condition that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No prior hormonal therapy

          -  No other concurrent hormonal therapy

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

        Other

          -  No other concurrent anticancer therapy
Clinical trial NCT01151137 (phase 3, status: terminated)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: dronedarone, placebo (for dronedarone)
SMILES: CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was stopped because of safety concerns
  
Eligibility criteria:

        Inclusion criteria:

          -  Permanent AF defined by the presence of all of the following criteria:

               -  Availability of one 12-lead ECG not more than 14 days prior to randomization
                  showing that the patient is in AF or atrial flutter;

               -  Availability of documentation (including either rhythm strips or medical report
                  of the rhythm) showing that the patient was in AF or atrial flutter at least 6
                  months prior to randomization;

               -  No evidence of sinus rhythm in the period between these two documentations of AF;

               -  Decision of the patient and physician to allow AF to continue without further
                  efforts to restore sinus rhythm.

          -  At least one of the following risk criteria:

               -  Coronary artery disease;

               -  Prior stroke or Transient Ischemic Attack [TIA];

               -  Symptomatic heart failure;

               -  Left ventricular ejection fraction [LVEF] less or equal to 0.40;

               -  Peripheral arterial occlusive disease;

               -  Aged 75 years or older with both hypertension and diabetes mellitus.

        Exclusion criteria:

          -  Paroxysmal AF;

          -  Persistent AF without a decision to allow AF to continue without further efforts to
             restore sinus rhythm;

          -  Heart failure of New-York Heart Association [NYHA] class IV or recent unstable NYHA
             class III.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00484419 (phase 3, status: completed)
Conditions: type 2 diabetes, hyperlipidemia
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, E78.2, E78.49, E78.5
Drugs: colesevelam hcl, rosiglitazone maleate, sitagliptin phosphate
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  HbA1C 7.0 % to 10.0% on metformin monotherapy; may be withdrawn from other
             (non-metformin) drugs if HbA1C is 6.5% to 9.5 % at screening.

        Exclusion Criteria:

          -  Subjects currently treated with a thiazolidinedione are excluded.
Clinical trial NCT00435760 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium bromide, placebo tiotropium, tiotropium, placebo las34273
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged ≥ 40 years

          -  Current or ex-smokers of ≥ 10 pack-year

          -  Clinical diagnosis of severe stable COPD

        Exclusion Criteria:

          -  History or current diagnosis of asthma, allergic rhinitis, or atopy

          -  Respiratory tract infection or acute COPD exacerbation in the last 6 weeks

          -  Hospitalised for an acute COPD exacerbation in the last 3 months

          -  Evidence of contraindicated use of anticholinergic drugs
Clinical trial NCT00116922 (phase 3, status: completed)
Conditions: impaired glucose tolerance, diabetes
ICD codes: R73.02, E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: avandamet [rosiglitazone 2mg/metformin 500mg] bid
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Residents of Ontario

          -  Age 18-75

          -  IGT on OGTT

        Exclusion Criteria:

          -  Current use of Metformin or Rosiglitazone

          -  Prior use of medication to treat diabetes except gestational diabetes

          -  Use of drugs known to exacerbate glucose tolerance

          -  History of diabetes except gestational diabetes

          -  Liver function studies greater the 2.5x normal

          -  Creatinine clearance less than 60 ml/min